In a month when the S&P devalued the stock market with its downgrade of the U.S.’ credit rating, it was encouraging to still see a strong level of investment in medical technologies, with investment in medtech at over $300 for the month.
In a month when the S&P devalued the stock market with its downgrade of the U.S.’ credit rating, it was encouraging to still see a strong level of investment in medical technologies, with investment in medtech at over $300 for the month. Top fundings included VIVUS raising $45.8 million in support of the company’s products in obesity, diabetes, apnea and others; Restoration Robotics raising $41 million for its image guidance system to be used in hair transplant procedures, Entellus Medical raising $35 million to fund development of its minimally invasive treatment of sinusitis and three separate $23 million financings for Vessix Vascular (RF balloon catheter for vascular occlusions), AccuVein (vein illumination device) and Fibrocell Sciences (autologous cell therapies).
The complete list of financings is available at link and illustrated below:
August 2011 Medtech Financings
Source: Compiled by MedMarket Diligence, LLC
